Articles tagged with Drug Targets
Researchers have identified a new approach to treating chronic graft-versus-host disease, targeting T and B cells with the FDA-approved drug ibrutinib. The study found that ibrutinib reduced chronic GVHD in mice models and decreased activation of T and B cells isolated from patients with chronic GVHD.
Researchers will sequence the genomes of 10,000 people with European, Hispanic, and African-American ancestry to better understand two mental health disorders. The goal is to identify genetic targets for drug development and improve disease prediction.
Researchers at Whitehead Institute have discovered a trio of poorly understood growth regulators called the Sestrins that play a crucial role in regulating mTORC1 signaling. The study found that the Sestrins work cooperatively to inhibit mTORC1 signaling by interacting with GATOR2, suggesting new potential targets for drug development.
A Harvard team developed a human airway muscle-on-a-chip that accurately mimics the way smooth muscle contracts in the human airway. The chip can be used to test new drugs and measure human responses to asthma triggers, paving the way for patient-specific treatments.
Researchers have identified a novel drug target, Kir7.1, that induces acute and sustained uterine contractions to treat postpartum haemorrhage (PPH), a major global cause of maternal mortality. The treatment bypasses biochemical pathways exhausted during prolonged labour, promising effective treatment at low doses.
UMass Amherst doctoral student Khaja Muneeruddin has received the 2014-15 Global Fellowship Award for developing new analytical methods to characterize complex pharmaceuticals. The award aims to advance research in quality standards and support his work on creating novel assays for drug manufacturers.
A commentary calls for physicians to carefully review older patients' medication lists and consider their anticipated life expectancy, goals of care, and treatment targets. This approach can help reduce the number of unnecessary prescriptions and minimize harm from medications in older adults.
Researchers develop a potential therapy for Sudan ebolavirus, showing promising results in laboratory tests and mouse models. The humanized antibody has been identified as an immunotherapeutic candidate to treat SUDV infection.
Researchers have discovered that glycoconjugate scaffolds are active players in biological reactions, influencing the binding of lectins to these molecules. This finding opens up new possibilities for developing more effective and targeted pharmaceuticals.
The NIH grant funds four collaborative projects, including those led by Dr. Robert Callender and Dr. Vern Schramm, who are working to understand the physics of atomic motions in enzymes. By doing so, they aim to design new classes of pharmaceuticals that can alleviate disease by targeting specific enzyme-substrate interactions.
A federal law aimed at reducing the use of 'club drugs' has failed, and instead put users at greater risk due to reduced access to safety measures like medical help and free water. The RAVE Act, enacted in 2003, targeted club owners but hindered their ability to provide necessary services.
Scientists at Johns Hopkins Bloomberg School of Public Health have discovered a new clue to understanding how the most important medication for tuberculosis works. The antibiotic Pyrazinamide cuts off the energy production of Mycobacterium tuberculosis, killing the bacteria by disrupting PanD, an enzyme crucial to synthesis of co-enzym...
MIT researchers have developed a new genome-editing technique using CRISPR to disrupt malaria genes with up to 100% success rate in weeks. This approach could accelerate the identification of novel therapeutic targets for malaria drugs and vaccines.
A new study by Yale researchers found that blocking the effects of PPARgamma in brain cells can prevent weight gain and resistance to high-fat diets. This discovery has key implications for treating type 2 diabetes, where weight gain is a common side effect of medication.
A new gene variant, PLXNA4, has been linked to an increased risk of developing Alzheimer's disease. The study found that this gene affects the processing of tau protein, a key hallmark of the disease. This discovery may lead to the development of targeted drug treatments for AD.
Researchers found that some microorganisms can use epimutations, a temporary silencing of drug targets, to gain drug resistance without committing to permanent mutations. This flexible mechanism could be employed by various organisms to withstand treatment with different drugs.
Researchers at Albert Einstein College of Medicine are developing a drug discovery project targeting Parkinson's disease using a newly identified target and chaperone-mediated autophagy. The goal is to develop a prototype drug that can treat the underlying cause of the disease.
Researchers have completed a comprehensive study on the role of protein phosphatases in malaria parasite development and differentiation. The study, published in Cell Host and Microbe, identifies 16 genes that are crucial for parasite growth and could be future drug targets.
Researchers at the Walter and Eliza Hall Institute have developed a compound that blocks Plasmepsin V, a critical enzyme essential for malaria parasite survival. The compound, WEHI-916, has shown promising results in killing malaria parasites and could lead to effective treatment of all species of the parasite.
Researchers at the Walter and Eliza Hall Institute developed a compound that blocks Plasmepsin V, a key enzyme essential for malaria parasite survival. This breakthrough could lead to new antimalarial drugs effective against all species of malaria parasites.
Scientists at Yerkes National Primate Research Center have identified a new drug target for preventing PTSD. Osanetant, which targets the Tac2 gene, has been shown to reduce fear memory consolidation in mice.
A researcher is using a $900,000 grant to resolve the debate on whether G protein-coupled receptors form dimers. He suspects that light transfer between constantly moving receptors may be random and not actual relationships. The study aims to find out how many drug targets are there and if they can help in treating various ailments.
SLU's Center for World Health and Medicine has received a $3.13 million sub-grant from PATH to explore new treatments for pediatric diarrhea, which kills about 600,000 young children worldwide each year. The grant aims to repurpose drugs for childhood diarrhea that pharmaceutical companies had developed as therapy for hypertension.
A research team led by Gong Chen has discovered a novel biomarker that targets excessive GABA inhibition in the brain's dentate gyrus, which correlates with poor memory performance in Alzheimer's disease models. Reducing this inhibitory neurotransmitter may lead to a new therapy for Alzheimer's disease.
The researchers designed a nanoparticle with a peptide coating to target tumor cells, allowing for efficient drug delivery. The shell is etchable, enabling the removal of excess particles using biocompatible chemicals.
Researchers from the University of Freiburg have made significant progress in understanding how the antimalarial drug atovaquone works. By analyzing its molecular structure, they have identified key binding sites and revealed the underlying mechanism of resistance to mutations. This breakthrough could lead to the development of more ef...
Researchers have uncovered three gene networks in autism that could lead to new treatments for attention-deficit hyperactivity disorder (ADHD) and schizophrenia. The networks, which affect neurotransmitter signaling, may also provide insights into the biological mechanisms underlying autism.
Recent advances in genetic research offer new hope for treating coronary artery disease by identifying specific genetic variants and pathways associated with cardiovascular risk. Human genetic data suggest that targeting LDL-C and triglycerides may be effective in reducing major cardiovascular events.
Researchers found that if all eye doctors prescribed the less expensive bevacizumab instead of ranibizumab for treating common eye diseases, Medicare could save $18 billion over a decade. This would also result in patients saving $4.6 billion in co-pays and the private healthcare system saving an additional $29 billion.
Researchers presented promising results from four clinical trials featuring new targeted drugs for advanced ovarian, lung and thyroid cancers, as well as chronic lymphocytic leukemia. These treatments showed potential to slow disease progression and improve survival rates for patients with relapses or treatment resistance.
A University of Colorado Cancer Center study found NTRK1 mutations in over 1% of non-small cell lung cancer patients. The study also developed a test for rapid detection of NTRK1 oncogenes, marking a new frontier in lung cancer treatment.
OMP-54F28, a Wnt inhibitor targeting cancer stem cells, has shown promising results in a Phase I clinical trial. The drug was generally well-tolerated and resulted in stable disease for over six months in several patients with advanced solid tumors.
A team at Cold Spring Harbor Laboratory has validated a potentially powerful new approach to treating HER2-positive breast cancer by inhibiting the protein PTP1B. The discovery may lead to improved treatments for the disease, which affects one in four patients and is often resistant to existing therapies.
A team of researchers created a database called K-Map that allows scientists to reposition existing drugs to treat various types of cancer. The database enables the evaluation of rational drugs and drug combinations, leading to new potential treatments such as bosutinib for non-small cell lung cancer.
Researchers at Cold Spring Harbor Laboratory have found a means of inhibiting PTP1B, which plays a critical role in the development of tumors in HER2-positive breast cancer. The discovery leads to the inhibition of tumor growth and prevention of metastasis.
A study by Memorial Sloan Kettering Cancer Center found that genomic tumor testing can improve survival for patients with advanced lung cancers. The test identified oncogenic drivers in 64% of tumors, leading to improved outcomes when matched with targeted therapies.
The Lancet publication highlights the need for accelerated action to reduce newborn mortality rates, citing a lack of registration and official recognition as a key barrier. The research suggests that scaling up achievable interventions can save three million lives by 2025.
Researchers have identified a new approach to treating brittle bone disease by targeting excessive activity of transforming growth factor beta, a signaling protein in the bone matrix. This novel treatment strategy shows promise for personalized and effective management of the condition, potentially applicable to osteoporosis as well.
Researchers found that pharmacist-led interventions show a significant improvement in blood pressure and cholesterol levels compared to current standard of care. Nurse-led care saw a 30% improvement, while pharmacist-led care achieved a 43% improvement in improving patient outcomes.
Researchers explore new approaches to managing intraocular fluid buildup in the trabecular meshwork, a key structure controlling eye pressure. The development of next-generation glaucoma therapies aims to improve treatment options for those at risk of glaucoma.
A new fruitfly study confirmed that the enzyme GABA transaminase, a target of some epilepsy drugs, contributes to sleep loss. The study sheds light on mechanisms connecting sleep disruption and neurological disorders.
A receptor called B7-1 is expressed by kidney cells during the progression of diabetic nephropathy, and targeting this receptor with abatacept helps to maintain kidney function in mice. The study suggests that clinical trials should be designed to test abatacept in diabetic patients.
Researchers have found that pramlintide reduces amyloid-beta peptides and improves learning and memory in Alzheimer's disease models. The study also suggests lower levels of amylin in blood among AD patients, which could lead to new diagnosis and treatment options.
Researchers at the University of York and University of Leeds have developed a mathematical model that explains the molecular mechanisms behind virus assembly. The discovery opens up possibilities for the development of anti-viral therapies and could help treat diseases such as HIV, Hepatitis B and C, Norovirus, and the Common Cold.
IDRI's drug discovery efforts continue with a $3.4 million grant extension from the Bill & Melinda Gates Foundation. The funding supports identifying new leads and drug targets for TB, a devastating disease killing 1.5 million annually.
Scientists are developing drugs that target the bacteria Wolbachia to kill parasitic worms causing river blindness and elephantiasis. The new treatment has already shown promise in depleting Wolbachia from infected worms.
Researchers identified key mutations and genetic disturbances that arise at certain stages of lung cancer development, including a gene called Mycl1 that is found in nearly all tumor cells. They also discovered that loss of the Pten gene leads to overactive cell growth and rapid tumor progression.
Researchers found that blocking a specific immune cell mediator can greatly reduce brain damage after a stroke. The study showed that treating mice with a compound that blocks IL-21 significantly reduced stroke damage and improved outcomes.
A new clinical study found that erlotinib significantly improved treatment outcomes for women with locally advanced cervical cancer. After two years, 91.7% of patients were alive and experienced no disease progression.
Researchers at Scripps Research Institute and Vanderbilt University have created the most detailed 3-D picture yet of a membrane protein linked to learning, memory, anxiety, pain and brain disorders. The study focused on the mGlu1 receptor, which helps regulate neurotransmitter glutamate.
A new study suggests that male hormones, such as testosterone, play an important role in female fertility and may enhance IVF success rates. The research found that male hormones promote follicle development by preventing cell death and increasing sensitivity to follicle-stimulating hormone.
Researchers have identified specific behavior of PP1 by analyzing binding motifs with regulatory proteins. This discovery allows them to predict interactions with a significant number of proteins without resolving their structure.
A large international study has found 11 new genetic signals linked to blood pressure levels, with 10 of those signals being 'druggable' targets. The discovery offers the possibility of expedited pharmaceutical development of therapeutics for high blood pressure, a serious risk factor for cardiovascular diseases.
Researchers at Clemson University have developed sticky nanoparticles that can deliver drugs targeting damaged arteries, providing a new method to fight heart disease. The nanoparticles, coated with a sticky protein, latch onto damaged arteries and release drugs in slow fashion, reducing the need for surgical interventions.
The cumulative success rate for new agents in advanced NSCLC is lower than industry estimates, but biomarker- and receptor-targeted therapies substantially increase success rates. Biomarker-targeted therapy shows a 62% cumulative success rate, nearly six times higher than non-biomarker targeted trials.
The 'Viewpoint' article highlights the complexity of developing genome-based therapeutics and companion diagnostics, which depend on multiple genetic tests. The authors argue for a unified plan to co-develop and co-submit diagnostic tests that predict drug benefit, addressing regulatory, business, and economic challenges.
Researchers identified four proteins involved in hantavirus entry into human host cells, all part of a protein complex regulating cholesterol production. Statins, commonly used to lower cholesterol, also showed promise in preventing viral infection.
Researchers have developed electronically controlled drugs that can minimize side effects by releasing medication in response to specific cues. These tailored approaches could be useful in treating conditions such as epilepsy, where medication could be released at the onset of a seizure.
Researchers have determined the complex structure of a key cell membrane protein involved in sterol metabolism and resistance in a yeast model. The study's findings provide new insights into mechanisms underlying fungal resistance to triazole drugs, which can help develop new broad-spectrum drugs with minimal side effects.
Scientists at UC Berkeley and NIH have captured a high-resolution snapshot of the Nef protein, which hijacks host proteins to facilitate HIV's lethality. By blocking a promising target on host protein AP2, researchers aim to slow or stop HIV.